lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR‑326/hnRNPA2B1 axis in liver cancer

Luo,Jun; Zheng,Jiaping; Hao,Weiyuan; Zeng,Hui; Zhang,Zhewei; Shao,Guoliang

doi:10.3892/ol.2021.12732

lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR‑326/hnRNPA2B1 axis in liver cancer

Authors:
- Jun Luo
- Jiaping Zheng
- Weiyuan Hao
- Hui Zeng
- Zhewei Zhang
- Guoliang Shao
View Affiliations

Affiliations: The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310022, P.R. China, Department of Intervention, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China
Published online on: April 13, 2021 https://doi.org/10.3892/ol.2021.12732
Article Number: 471
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer is one of the most common malignant human tumors with the highest morbidity and mortality rates of all cancer types in China. Evidence suggests that long non‑coding RNA prostate cancer‑associated transcript 6 (PCAT6) plays an essential role in tumor progression. However, the roles and mechanism of PCAT6 in liver cancer remain unclear. The present study showed that the expression of PCAT6 and heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) was upregulated in liver cancer tissues compared with non‑cancerous tissues and were associated with poor overall survival time, whereas microRNA (miR)‑326 expression was downregulated. Moreover, knockdown of PCAT6 significantly inhibited the proliferation and invasion of liver cancer cells in vitro and in vivo. A dual‑luciferase reporter gene assay demonstrated that PCAT6 could bind to miR‑326 and that hnRNPA2B1 was a direct target gene of miR‑326. Mechanistically, silenced PCAT6 suppressed the malignant phenotype of liver cancer cells through upregulating the inhibitory effect of miR‑326 on hnRNPA2B1 expression. Taken together, these data demonstrated that knockdown of PCAT6 inhibited liver cancer progression through regulation of the miR‑326/hnRNPA2B1 axis, suggesting that PCAT6 functions as an oncogene and may be a useful biomarker for the future diagnosis and treatment of liver cancer.

View Figures

View References

1	Global Burden of Disease Liver Cancer Collaboration, ; Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, et al: The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015. JAMA Oncol. 3:1683–1691. 2017. View Article : Google Scholar : PubMed/NCBI
2	Mavros MN, Mayo SC, Hyder O and Pawlik TM: A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 215:820–830. 2012. View Article : Google Scholar : PubMed/NCBI
3	Tan N, Zhu B, Shu H, Tao YF, Wu JR, Fang M, Li CR, Chen ZQ and Ou C: Effect of lncRNA-BC200 on proliferation and migration of liver cancer cells in vitro and in vivo. Oncol Rep. 43:461–470. 2020.PubMed/NCBI
4	Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, DAngelica M, Abou-Alfa G, Blumgart LH and DeMatteo RP: Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 106:1331–1338. 2006. View Article : Google Scholar : PubMed/NCBI
5	Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D and Ferrell LD: Clinicopathologic features and survival in fibrolamellar carcinoma: Comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 18:1417–1423. 2005. View Article : Google Scholar : PubMed/NCBI
6	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
7	Arun G, Diermeier SD and Spector DL: Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 24:257–277. 2018. View Article : Google Scholar : PubMed/NCBI
8	Liu Y, Feng W, Liu W, Kong X, Li L, He J, Wang D, Zhang M, Zhou G, Xu W, et al: Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. J Cancer. 10:3746–3756. 2019. View Article : Google Scholar : PubMed/NCBI
9	Chi Y, Wang D, Wang J, Yu W and Yang J: Long non-coding RNA in the pathogenesis of cancers. Cells. 8:10152019. View Article : Google Scholar : PubMed/NCBI
10	Zhong G, Wang K, Li J, Xiao S, Wei W and Liu J: Determination of serum exosomal H19 as a noninvasive biomarker for breast cancer diagnosis. Onco Targets Ther. 13:2563–2571. 2020. View Article : Google Scholar : PubMed/NCBI
11	Xu W, Zhou G, Wang H, Liu Y, Chen B, Chen W, Lin C, Wu S, Gong A and Xu M: Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer. Int J Cancer. 146:2901–2912. 2020. View Article : Google Scholar : PubMed/NCBI
12	Zhang G, Chi N, Lu Q, Zhu D and Zhuang Y: LncRNA PTCSC3 is a biomarker for the treatment and prognosis of gastric cancer. Cancer Biother Radiopharm. 35:77–81. 2020. View Article : Google Scholar : PubMed/NCBI
13	Yao Z, Zhang Y, Xu D, Zhou X, Peng P, Pan Z, Xiao N, Yao J and Li Z: Research progress on long non-coding RNA and radiotherapy. Med Sci Monit. 25:5757–5770. 2019. View Article : Google Scholar : PubMed/NCBI
14	Wan L, Zhang L, Fan K, Cheng ZX, Sun QC and Wang JJ: Knockdown of long noncoding RNA PCAT6 inhibits proliferation and invasion in lung cancer cells. Oncol Res. 24:161–170. 2016. View Article : Google Scholar : PubMed/NCBI
15	Bai F, Zhang N, Fang W, He X, Zheng Y and Gu D: PCAT6 mediates cellular biological functions in gastrointestinal stromal tumor via upregulation of PRDX5 and activation of Wnt pathway. Mol Carcinog. 59:661–669. 2020. View Article : Google Scholar : PubMed/NCBI
16	Huang W, Su G, Huang X, Zou A, Wu J, Yang Y, Zhu Y, Liang S, Li D, Ma F and Guo L: Long noncoding RNA PCAT6 inhibits colon cancer cell apoptosis by regulating anti-apoptotic protein ARC expression via EZH2. Cell Cycle. 18:69–83. 2019. View Article : Google Scholar : PubMed/NCBI
17	Zhu C, Huang L, Xu F, Li P, Li P and Hu F: LncRNA PCAT6 promotes tumor progression in osteosarcoma via activation of TGF-β pathway by sponging miR-185-5p. Biochem Biophys Res Commun. 521:463–470. 2020. View Article : Google Scholar : PubMed/NCBI
18	Tang X, Feng D, Li M, Zhou J, Li X, Zhao D, Hao B, Li D and Ding K: Transcriptomic analysis of mRNA-lncRNA-miRNA interactions in hepatocellular carcinoma. Sci Rep. 9:160962019. View Article : Google Scholar : PubMed/NCBI
19	Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V, et al: Hepatocellular carcinoma treatment over sorafenib: Epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 19:1623–1635. 2015. View Article : Google Scholar : PubMed/NCBI
20	He S, Yang J, Jiang S, Li Y and Han X: Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis. Cancer Cell Int. 20:4042020. View Article : Google Scholar : PubMed/NCBI
21	Council for International Organizations of Medical Sciences (CIOMS), . International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS; Geneva: pp. p602002
22	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
23	Zheng J, Luo J, Zeng H, Guo L and Shao G: ¹²⁵I suppressed the Warburg effect via regulating miR-338/PFKL axis in hepatocellular carcinoma. Biomed Pharmacother. 119:1094022019. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Zeng H, Zheng J, Wen S, Luo J, Shao G and Zhang Y: MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689. Drug Des Devel Ther. 13:435–445. 2019. View Article : Google Scholar : PubMed/NCBI
26	Li JH, Liu S, Zhou H, Qu LH and Yang JH: starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
27	Li HW and Liu J: Circ_0009910 promotes proliferation and metastasis of hepatocellular carcinoma cells through miR-335-5p/ROCK1 axis. Eur Rev Med Pharmacol Sci. 24:1725–1735. 2020.PubMed/NCBI
28	Liu Y and Shi SL: The roles of hnRNP A2/B1 in RNA biology and disease. Wiley Interdiscip Rev RNA. 12:e16122021. View Article : Google Scholar : PubMed/NCBI
29	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
30	Chen J, Zhang Y, Chen Y and Ding L: Incidence trend of liver cancer: An analysis of 40 years data from Qidong population-based cancer registry. Zhongguo Zhong Liu. 23:621–628. 2014.PubMed/NCBI
31	Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, Lu P, Hsia CC, Wang N, Xu L, et al: Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 34:1800–1805. 2013. View Article : Google Scholar : PubMed/NCBI
32	Kondo Y, Shinjo K and Katsushima K: Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci. 108:1927–1933. 2017. View Article : Google Scholar : PubMed/NCBI
33	Camacho CV, Choudhari R and Gadad SS: Long noncoding RNAs and cancer, an overview. Steroids. 133:93–95. 2018. View Article : Google Scholar : PubMed/NCBI
34	Sun Y, Zhang F, Wang L, Song X, Jing J, Zhang F, Yu S and Liu H: A five lncRNA signature for prognosis prediction in hepatocellular carcinoma. Mol Med Rep. 19:5237–5250. 2019.PubMed/NCBI
35	Cai C, Yang L, Tang Y, Wang H, He Y, Jiang H and Zhou K: Prediction of overall survival in gastric cancer using a nine-lncRNA. DNA Cell Biol. 38:1005–1012. 2019. View Article : Google Scholar : PubMed/NCBI
36	Wan L, Zhang L, Fan K and Wang JJ: Diagnostic significance of circulating long noncoding RNA PCAT6 in patients with non-small cell lung cancer. Onco Targets Ther. 10:5695–5702. 2017. View Article : Google Scholar : PubMed/NCBI
37	Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
38	Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q, Tong X, Yang W, Xu Q, Huang D and Tu K: A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 18:282019. View Article : Google Scholar : PubMed/NCBI
39	Shi X, Liu Z, Liu Z, Feng X, Hua F, Hu X, Wang B, Lu K and Nie F: Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer. EBioMedicine. 37:177–187. 2018. View Article : Google Scholar : PubMed/NCBI
40	Lv XJ, Tang Q, Tu YQ, Yan DD and Wei QC: Long noncoding RNA PCAT6 regulates cell growth and metastasis via Wnt/β-catenin pathway and is a prognosis marker in cervical cancer. Eur Rev Med Pharmacol Sci. 23:1947–1956. 2019.PubMed/NCBI
41	Wu H, Zou Q, He H, Liang Y, Lei M, Zhou Q, Fan D and Shen L: Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. Cancer Med. 8:2484–2495. 2019. View Article : Google Scholar : PubMed/NCBI
42	Shi R, Wu P, Liu M, Chen B and Cong L: Knockdown of lncRNA PCAT6 enhances radiosensitivity in triple-negative breast cancer cells by regulating miR-185-5p/TPD52 axis. Onco Targets Ther. 13:3025–3037. 2020. View Article : Google Scholar : PubMed/NCBI
43	Lin C, Yuan G, Hu Z, Zeng Y, Qiu X, Yu H and He S: Bioinformatics analysis of the interactions among lncRNA, miRNA and mRNA expression, genetic mutations and epigenetic modifications in hepatocellular carcinoma. Mol Med Rep. 19:1356–1364. 2019.PubMed/NCBI
44	Dong D, Lun Y, Sun B, Sun H, Wang Q, Yuan G and Quan J: Silencing of long non-coding RNA PCAT6 restrains gastric cancer cell proliferation and epithelial-mesenchymal transition by targeting microRNA-15a. Gen Physiol Biophys. 39:1–12. 2020. View Article : Google Scholar : PubMed/NCBI
45	Zou X, Zhong J, Li J, Su Z, Chen Y, Deng W, Li Y, Lu S, Lin Y, Luo L, et al: miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells. Mol Med Rep. 13:994–1002. 2016. View Article : Google Scholar : PubMed/NCBI
46	Wang D, Wang H, Li Y and Li Q: MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma. Biosci Rep. 38:BSR201806682018. View Article : Google Scholar : PubMed/NCBI
47	Lu M, Kong X, Wang H, Huang G, Ye C and He Z: A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget. 8:8775–8784. 2017. View Article : Google Scholar : PubMed/NCBI
48	Hu S, Ran Y, Chen W, Zhang Y and Xu Y: MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1. Oncol Rep. 38:1569–1578. 2017. View Article : Google Scholar : PubMed/NCBI
49	Mo Y, He L, Lai Z, Wan Z, Chen Q, Pan S, Li L, Li D, Huang J, Xue F and Che S: Gold nano-particles (AuNPs) carrying miR-326 targets PDK1/AKT/c-myc axis in hepatocellular carcinoma. Artif Cells Nanomed Biotechnol. 47:2830–2837. 2019. View Article : Google Scholar : PubMed/NCBI
50	Ma J, Wang T, Guo R, Yang X, Yin J, Yu J, Xiang Q, Pan X, Tang H and Lei X: Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. J Drug Target. 23:519–524. 2015. View Article : Google Scholar : PubMed/NCBI
51	Song W, Qian Y, Zhang MH, Wang H, Wen X, Yang XZ and Dai WJ: The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer. Eur Rev Med Pharmacol Sci. 24:3049–3061. 2020.PubMed/NCBI
52	Yu W, Peng W, Sha H and Li J: Hsa_circ_0003998 promotes chemoresistance via modulation of miR-326 in lung adenocarcinoma cells. Oncol Res. 27:623–628. 2019. View Article : Google Scholar : PubMed/NCBI
53	Mizuno H, Honda M, Shirasaki T, Yamashita T, Yamashita T, Mizukoshi E and Kaneko S: Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma. Liver Int. 32:1146–1155. 2012. View Article : Google Scholar : PubMed/NCBI
54	Wang H, Liang L, Dong Q, Huan L, He J, Li B, Yang C, Jin H, Wei L, Yu C, et al: Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma. Theranostics. 8:2814–2829. 2018. View Article : Google Scholar : PubMed/NCBI
55	Yang Y, Wei Q, Tang Y, Wang Y, Luo Q, Zhao H, He M, Wang H, Zeng Q, Lu W, et al: Loss of hnRNPA2B1 inhibits malignant capability and promotes apoptosis via down-regulating Lin28B expression in ovarian cancer. Cancer Lett. 475:43–52. 2020. View Article : Google Scholar : PubMed/NCBI
56	Shi X, Ran L, Liu Y, Zhong SH, Zhou PP, Liao MX and Fang W: Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway. Oncol Rep. 39:939–950. 2018.PubMed/NCBI